MX2018005258A - Ensayos basados en células para la detección de anticuerpos u otros factores que neutralizan la absorción de enzimas lisosómicas. - Google Patents

Ensayos basados en células para la detección de anticuerpos u otros factores que neutralizan la absorción de enzimas lisosómicas.

Info

Publication number
MX2018005258A
MX2018005258A MX2018005258A MX2018005258A MX2018005258A MX 2018005258 A MX2018005258 A MX 2018005258A MX 2018005258 A MX2018005258 A MX 2018005258A MX 2018005258 A MX2018005258 A MX 2018005258A MX 2018005258 A MX2018005258 A MX 2018005258A
Authority
MX
Mexico
Prior art keywords
factors
cell
antibodies
uptake
neutralize
Prior art date
Application number
MX2018005258A
Other languages
English (en)
Inventor
Melton Andrew
ZOOG Stephen
Jesaitis Lynne
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of MX2018005258A publication Critical patent/MX2018005258A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4915—Blood using flow cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G01N33/5434—Magnetic particles using magnetic particle immunoreagent carriers which constitute new materials per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a métodos basados en células para detectar tejidos o fluidos corporales por factores que evitan la absorción celular de enzimas lisosómicas, que incluyen factores neutralizantes tales como anticuerpos neutralizantes, que surgen como resultado de la terapia de remplazo de enzima lisosómica.
MX2018005258A 2015-11-06 2016-11-07 Ensayos basados en células para la detección de anticuerpos u otros factores que neutralizan la absorción de enzimas lisosómicas. MX2018005258A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562252181P 2015-11-06 2015-11-06
PCT/US2016/060795 WO2017079729A1 (en) 2015-11-06 2016-11-07 Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes

Publications (1)

Publication Number Publication Date
MX2018005258A true MX2018005258A (es) 2019-09-04

Family

ID=57321463

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005258A MX2018005258A (es) 2015-11-06 2016-11-07 Ensayos basados en células para la detección de anticuerpos u otros factores que neutralizan la absorción de enzimas lisosómicas.

Country Status (9)

Country Link
US (1) US11262348B2 (es)
EP (1) EP3371593B1 (es)
JP (1) JP2018538008A (es)
CN (1) CN108474788A (es)
AU (1) AU2016349528A1 (es)
CA (1) CA3003750A1 (es)
HK (1) HK1253529A1 (es)
MX (1) MX2018005258A (es)
WO (1) WO2017079729A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116930475A (zh) * 2022-03-31 2023-10-24 上海细胞治疗集团药物技术有限公司 中和抗体检测方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7485314B2 (en) 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
CA2553955C (en) 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
ATE511645T1 (de) 2006-03-17 2011-06-15 Biomarin Pharm Inc Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme
KR101744142B1 (ko) 2008-01-18 2017-06-07 바이오마린 파머수티컬 인크. 활성이고 높은 정도로 인산화된 인간 리소좀 술파타아제 효소의 제조 및 그 용도
EP3272773B8 (en) 2008-05-07 2020-11-18 BioMarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
US8962573B2 (en) * 2009-07-03 2015-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compounds targeting the cation-independent mannose 6-phosphate receptor
EP2699676A1 (en) 2011-04-22 2014-02-26 Genzyme Corporation Modified acid alpha glucosidase with accelerated processing
ES2660185T3 (es) 2011-05-27 2018-03-21 Amicus Therapeutics, Inc. Métodos para acoplar péptidos direccionadores a enzimas lisosomales recombinantes para optimizar los tratamientos de las enfermedades por depósito lisosomal
ES2729997T3 (es) 2012-11-27 2019-11-07 Biomarin Pharm Inc Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas

Also Published As

Publication number Publication date
HK1253529A1 (zh) 2019-06-21
EP3371593B1 (en) 2020-10-14
AU2016349528A1 (en) 2018-05-17
US20180321221A1 (en) 2018-11-08
CA3003750A1 (en) 2017-05-11
EP3371593A1 (en) 2018-09-12
WO2017079729A1 (en) 2017-05-11
JP2018538008A (ja) 2018-12-27
US11262348B2 (en) 2022-03-01
CN108474788A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
MX2017006094A (es) Anticuerpos anti-interleucina-33 y sus usos.
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MX2017010836A (es) Panel biomarcador para la deteccion de cancer.
MA33894B1 (fr) Procedes d'administration therapeutique de la pirferidone
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
NZ718280A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2018001353A (es) Ensayos dispersables en agua.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2019010769A (es) Proceso para la preparacion de enlazadores de farmacos de glucuronidos y compuestos intermediarios de los mismos.
MX354303B (es) Anticuerpos de anti-biotina y metodos de uso.
MX2017000840A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer.
MX2023006415A (es) Anticuerpos, usos y metodos.
WO2018136919A3 (en) Methods relating to lung cancer
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
EP3736022A3 (en) Treatment and diagnosis of colon cancer
EP3693742A3 (en) Methods of detecting prostate cancer
MX2018004606A (es) Spodoptera frugiperda resistente a proteina insecticida vegetativa 3a (vip3a).
PH12019502075A1 (en) A liquid formulation of anti-tnf alpha antibody
WO2017181163A3 (en) Methods and compositions for detection and diagnosis of breast cancer
MX2015009153A (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.